Moderna's combined flu and COVID-19 mRNA vaccine shows durable immune response in mid-stage trial
By
Stephanie Soucheray, MA
Front-window bakery material. Catches the eye, delivers the goods.
Summary
Moderna announced promising results from a mid-stage trial of its combined mRNA seasonal flu and COVID-19 vaccine (mRNA-1073). The study involved 550 healthy US adults aged 18-75 and showed that a single dose of the combo vaccine produced robust and durable immune responses against both influenza and SARS-CoV-2 strains through 6 months, with no serious safety concerns.
Key quotes
· 3 pulledModerna announced late last week that its mRNA combined seasonal flu and COVID-19 vaccine proved robust and produced a durable immune response in a small, mid-stage trial.
There were also no serious safety concerns.
A single dose of mRNA-1073 elicited durable immune responses through 6 months against all vaccine-matched influenza and SARS-CoV-2 strains.
You might also wanna read
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and mas
statnews.com·7mo ago
Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
jamanetwork.com·6mo ago
FDA Issues Refusal-to-File Letter to Moderna for mRNA Influenza Vaccine
The article criticizes the FDA's recent actions under the new administration, particularly focusing on a Refusal-to-File (RTF) letter issued
marginalrevolution.com·4mo ago
HHS Ends mRNA Vaccine Development Under BARDA Following Review
The U.S. Department of Health and Human Services (HHS) has announced the wind-down of its mRNA vaccine development activities under BARDA, i
hhs.gov·10mo ago